Unmet Medical Need
The World is Dangerously Underinvesting in New Antifungal Drugs.
|
Only three classes of molecules are currently used in clinical practice and only one new class of antifungal drugs has been developed in the last 30 years. Meanwhile, the use of already marketed antifungals continues to increase, not least because of their extended use as fungicides in agricultural and livestock production. Not surprisingly, Multidrug Resistance (MDR) is emerging as a serious global health threat for several fungal strains. This paradoxical situation has only intensified as the pharmaceutical industry focuses its attention on more lucrative medical indications such as cancer, cardiovascular- and neurological diseases. Indeed, over the last few years several global pharmaceutical companies have left the antimicrobial and antifungal field entirely. |
Biosergen Addresses One of the Worst Unmet Medical Needs: Invasive Fungal Diseases
|
|
Opportunistic fungal infections Are increasing because the number of people with weakened immune systems continues to increase |
 |
Majority of systemic fungal infection-related deaths are caused by four fungal pathogens: Candida, Aspergillus, Cryptococcus and Pneumocystis |
|
|
Hospital acquired infections Has multiple causes, including inadequate sanitation protocols and the routine use of antifungal drugs that creates a selection pressure for the emergence of resistant strains |
|
Emerging multidrug resistant (MDR) fungal pathogens |
|
|
Community acquired infections These outbreaks are almost certainly linked to demographic changes and climate change |
|
Big-pharma has been pulling out |
| This situation is now recognized by the WHO, CDC and others as a global health threat |
